scholarly journals Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.

Circulation ◽  
1984 ◽  
Vol 70 (4) ◽  
pp. 599-605 ◽  
Author(s):  
Y Yui ◽  
R Hattori ◽  
Y Takatsu ◽  
H Nakajima ◽  
A Wakabayashi ◽  
...  
Keyword(s):  
Platelet Aggregation ◽  
Intravenous Infusion ◽  
Thromboxane A2 ◽  
Selective Inhibitor ◽  
Thromboxane B2

Mariannaeapyrone -a New Inhibitor of Thromboxane A2 Induced Platelet Aggregation

2001 ◽  
Vol 56 (1-2) ◽  
pp. 106-110 ◽  
Author(s):  
Kerstin Fabian ◽  
Timm Anke ◽  
Olov Sterner
Keyword(s):  
Platelet Aggregation ◽  
Chemical Structure ◽  
Thromboxane A2 ◽  
Human Platelets ◽  
Selective Inhibitor ◽  
Spectroscopic Techniques ◽  
Fungal Metabolite ◽  
Antimicrobial Effects ◽  
The Common ◽  
Induced Aggregation

Abstract Mariannaeapyrone ((E)-2-(1,3,5,7-tetramethyl-5-nonenyl)-3,5-dimethyl-6-hydroxy-4H-pyran-4-one) is a new fungal metabolite isolated from fermentations of the common mycophilic deuteromycete Mariannaea elegans. The chemical structure of the 4-pyrone was determined by spectroscopic techniques. Mariannaeapyrone is a selective inhibitor of the thromboxane A2 induced aggregation of human platelets, whereas only weak cytotoxic and antimicrobial effects could be observed.

scholarly journals Prostaglandin Endoperoxides and Thromboxanes: Role in Platelets

1977 ◽  
Author(s):  
Bengt Samuelsson
Keyword(s):  
Smooth Muscle ◽  
Platelet Aggregation ◽  
Vascular Smooth Muscle ◽  
Thromboxane A2 ◽  
Human Platelets ◽  
Thromboxane B2 ◽  
Structural Work

Two groups of unstable (t1/2=5 min) endoperoxides, PGG and PGH compounds, have been isolated and shown to be precursors of the prostaglandins. The endoperoxides cause platelet aggregation and contract vascular and air-way smooth muscle.A new group of compounds(thromboxanes) derived from the endoperoxides has been discovered. A highly unstable(t1/2=30-40 sec) intermediate, thromboxane A2, between the endoperoxides and thromboxane B2 has been detected. Structural work indicates that it has a bicyclic oxane-oxetane structure. Thromboxane A2 is a potent aggregating agent with pronounced effects on vascular smooth muscle. Studies on the mechanisms of actions of the endoperoxides and thromboxanes in human platelets will be discussed.

Effect of Indomethacin and Dazoxiben on Intravascular Platelet Aggregation in the Anaesthetized Rabbit

1986 ◽  
Vol 56 (01) ◽  
pp. 080-085 ◽  
Author(s):  
A C Honey ◽  
N Lad ◽  
D P Tuffin
Keyword(s):  
Platelet Aggregation ◽  
Plasma Levels ◽  
Thromboxane A2 ◽  
Adenosine Diphosphate ◽  
Thromboxane B2 ◽  
Bolus Intravenous Injection ◽  
Cyclic Endoperoxide ◽  
High Doses ◽  
Synthetic Capacity ◽  
Dose Dependent

Summary Collagen (10-40 μg kg−1), thrombin (1-10 units kg−1), adenosine diphosphate (ADP; 3-300 pμ kg−1), 1-0-hexadecyl Paf-acether and 1-0-octadecyl Paf-acether (1-300 ng kg−1) administered by bolus intravenous injection each caused dose-dependent thrombocytopoenia accompanied by marked hypotension in anaesthetized rabbits. Responses to ADP and the Paf-acether derivatives were transient in nature (3-8 min) whereas those induced by collagen and thrombin were always of longer duration (5-20 min) and frequently fatal at high doses. Responses to collagen, thrombin, and the Paf-acether derivatives were invariably accompanied by substantial, dose-related increases in plasma levels of thromboxane B2 in samples obtained 30 s after agonist administration, whereas following ADP, no change in plasma thromboxane B2 was detected at any dose level. Indomethacin (3.0 mg kg−1 by infusion) had no effect on responses to thrombin or Paf-acether, partially inhibited collagen-induced thrombocytopenia, and potentiated responses to ADP. In contrast, dazoxiben (10 mg kg−1 by infusion) partially but significantly inhibited responses to thrombin, whereas those induced by collagen, Paf-acether or ADP were unchanged. These results indicate that in this model of intravascular aggregation, whilst platelet responses to collagen and thrombin appear partially dependent on intact cyclic endoperoxide and thromboxane A2 synthetic capacity respectively, responses to ADP and Paf-acether are independent of arachidonate metabolism via cyclo-oxygenase despite measurably increased TXB2 formation in the latter case.

Effect of Tranylcypromine on Platelet Aggregation Induced by Thrombin, ADP, Adrenaline, Collagen and Arachidonic ACID

1979 ◽  
Author(s):  
C. Busch ◽  
C. Ljungman ◽  
L. Birgersson
Keyword(s):  
Arachidonic Acid ◽  
Endothelial Cell ◽  
Platelet Aggregation ◽  
Thromboxane A2 ◽  
Inhibitory Effect ◽  
Selective Inhibitor ◽  
The Other ◽  
Common Pathway ◽  
Prostacyclin Synthesis ◽  
Platelet Functions

The monoaminooxidase inhibitor tranylcypromine has been suggested to be a selective inhibitor of prostacyclin synthetase with no inhibitory effect on thromboxane A2 formation in platelets. The substance would then be a suitable tool for discrimination between prostacyclin synthesis and release on one hand and other possible thrombocytophobic properties of the endothelial cell particularly its surface on the other. This study, however, shows that tranylcypromine interferes with platelet aggregation induced by thrombin, ADP, adrenaline and collagen whereas that of arachidonic acid is not affected. The results indicate an inhibition at an earlier common pathway of platelet aggregation than the metabolism of arachidonic acid. It is also suggested that the search for a selective inhibitor of prostacyclin synthesis which does not interfere with platelet functions should continue.

Mepacrine Blockade of Arachidonate-lnduced Washed Platelet Aggregation: Relationship to Mepacrine Inhibition of Platelet Cyclooxygenase

1983 ◽  
Vol 50 (04) ◽  
pp. 784-786 ◽  
Author(s):  
Amiram Raz
Keyword(s):  
Arachidonic Acid ◽  
Platelet Aggregation ◽  
Thromboxane A2 ◽  
Inhibitory Effect ◽  
Thromboxane B2 ◽  
Concomitant Increase ◽  
Dependent Inhibition ◽  
Dose Dependent Inhibition ◽  
Arachidonate Release ◽  
Dose Dependent

SummaryMepacrine, in addition to its established antilipolytic activity, was also found to inhibit the conversion of 14C-arachidonic acid to 14C-thromboxane B2 in human washed platelets. In the concentration range of 3.33-33 μM, mepacrine exerted a dose dependent inhibition of arachidonate conversion to thromboxane B2 in parallel to inhibition of arachidonate-induced platelet aggregation. Mepacrine inhibition of thromboxane formation was not accompanied by a concomitant increase in other cyclooxygenase products. Furthermore, mepacrine did not affect platelet transformation of added prostaglandin H2 to thromboxane A2 and other products. These results indicate that mepacrine inhibits the cyclooxygenase enzyme and not thromboxane synthase. In washed platelets, mepacrine inhibition of arachidonic acid conversion to thromboxane A2 appears to be a major factor in the overall inhibitory effect of the compound on the combined process of arachidonate release from cellular phospholipids and its conversion to proaggregatory products.

Effect of Vitamin E on Platelet Aggregation in Diabetes Mellitus

1984 ◽  
Vol 51 (03) ◽  
pp. 313-316 ◽  
Author(s):  
J Watanabe ◽  
F Umeda ◽  
H Wakasugi ◽  
H Ibayashi
Keyword(s):  
Vitamin E ◽  
Platelet Aggregation ◽  
Vascular Complications ◽  
Thromboxane A2 ◽  
Adenosine Diphosphate ◽  
Thromboxane B2 ◽  
Enhanced Production ◽  
Thromboxane Production ◽  
And Control ◽  
Platelet Thromboxane

SummaryVitamin E is known to be an inhibitor of platelet prostaglandin production and aggregation. The rate of platelet aggregation induced by adenosine diphosphate was significantly increased in diabetics with proliferative retinopathy and the enhanced production of thromboxane B2, a stable metabolite of thromboxane A2, was demonstrated in those patients. On the other hand, vitamin E in platelets was significantly reduced in diabetics compared with age matched controls. In addition, it was shown that vitamin E content in platelets examined in diabetic and control subjects inversely correlated with both the rate of platelet aggregation and thromboxane B2 production during aggregation. It is suggested that the reduced vitamin E levels in diabetic platelets can contribute to the mechanisms of the enhanced platelet thromboxane production and aggregation which relate to the development of vascular complications.

Stimulated Platelet Aggregation, Thromboxane B2 Formation and Platelet Sensitivity to Prostacyclin - A Critical Evaluation

1981 ◽  
Vol 45 (03) ◽  
pp. 204-207 ◽  
Author(s):  
Wolfgang Siess ◽  
Peter Roth ◽  
Peter C Weber
Keyword(s):  
Arachidonic Acid ◽  
Platelet Count ◽  
Platelet Aggregation ◽  
Reliable Method ◽  
Platelet Rich Plasma ◽  
Critical Evaluation ◽  
Vascular Diseases ◽  
Thromboxane B2 ◽  
Test Time ◽  
Stimulation Of

SummaryPlatelets have been implicated in the development of atherosclerotic and thrombotic vascular diseases. Evaluation of platelet aggregation in relation to endogenously formed compounds which affect platelet function may provide information of clinical and pharmacological relevance. We describe a method in which thromboxane B2 (TXB2) formation was analyzed following stimulation of platelet-rich plasma (PRP) with ADP, 1-epinephrine, collagen, and arachidonic acid. In addition, we determined platelet sensitivity to prostacyclin following ADP- and collagen-induced platelet aggregation. The parameters under study were found to depend on the platelet count in PRP, on the type and dose of the aggregating agent used, and on the test time after blood sampling. By standardization of these variables, a reliable method was established which can be used in clinical and pharmacological trials.

Trimucytin: A Collagen-Like Aggregating Inducer Isolated from Trimeresurus mucrosquamatus Snake Venom

1993 ◽  
Vol 69 (03) ◽  
pp. 286-292 ◽  
Author(s):  
Che-Ming Teng ◽  
Feng-Nien Ko ◽  
Inn-Ho Tsai ◽  
Man-Ling Hung ◽  
Tur-Fu Huang
Keyword(s):  
Platelet Aggregation ◽  
Snake Venom ◽  
Inositol Phosphate ◽  
Shape Change ◽  
Platelet Activating Factor ◽  
Atp Release ◽  
Platelet Membrane ◽  
Thromboxane B2 ◽  
Dependent Manner ◽  
Concentration Dependent Manner

SummaryTrimucytin is a potent platelet aggregation inducer isolated from Trimeresurus mucrosquamatus snake venom. Similar to collagen, trimucytin has a run of (Gly-Pro-X) repeats at the N-terminal amino acids sequence. It induced platelet aggregation, ATP release and thromboxane formation in rabbit platelets in a concentration-dependent manner. The aggregation was not due to released ADP since it was not suppressed by creatine phosphate/creatine phosphokinase. It was not either due to thromboxane A2 formation because indomethacin and BW755C did not have any effect on the aggregation even thromboxane B2 formation was completely abolished by indomethacin. Platelet-activating factor (PAF) was not involved in the aggregation since a PAF antagonist, kadsurenone, did not affect. However, RGD-containing peptide triflavin inhibited the aggregation, but not the release of ATP, of platelets induced by trimucytin. Indomethacin, mepacrine, prostaglandin E1 and tetracaine inhibited the thromboxane B2 formation of platelets caused by collagen and trimucytin. Forskolin and sodium nitroprusside inhibited both platelet aggregation and ATP release, but not the shape change induced by trimucytin. In quin-2 loaded platelets, the rise of intracellular calcium concentration caused by trimucytin was decreased by 12-O-tetradecanoyl phorbol-13 acetate, imipramine, TMB-8 and indomethacin. In the absence of extracellular calcium, both collagen and trimucytin caused no thromboxane B2 formation, but still induced ATP release which was completely blocked by R 59022. Inositol phosphate formation in platelets was markedly enhanced by trimucytin and collagen. MAB1988, an antibody against platelet membrane glycoprotein Ia, inhibited trimucytinand collagen-induced platelet aggregation and ATP release. However, trimucytin did not replace the binding of 125I-labeled MAB1988 to platelets. Platelets pre-exposed to trimucytin were resistant to the second challenge with trimucytin itself or collagen. It is concluded that trimucytin may activate collagen receptors on platelet membrane, and cause aggregation and release mainly through phospholipase C-phosphoinositide pathway.

Platelet Aggregation in Whole Blood: The Role of Thromboxane A2 and Adenosine Diphosphate

1985 ◽  
Vol 54 (03) ◽  
pp. 612-616 ◽  
Author(s):  
A J Carter ◽  
S Heptinstall
Keyword(s):  
Platelet Aggregation ◽  
Whole Blood ◽  
Adenosine Diphosphate ◽  
Blood Platelet ◽  
Thromboxane B2 ◽  
Lipoxygenase Inhibitor ◽  
Thromboxane Synthase Inhibitor ◽  
Synthase Inhibitor

SummaryThe platelet aggregation that occurred in whole blood in response to several aggregating agents (collagen, arachidonic acid, adenosine diphosphate, adrenaline and thrombin) was measured using an Ultra-Flo 100 Whole Blood Platelet Counter. The amounts of thromboxane B2 produced were measured by radioimmunoassay. The effects of various inhibitors of thromboxane synthesis and the effects of apyrase, an enzyme that destroys adenosine diphosphate, were determined.Platelet aggregation was always accompanied by the production of thromboxane B2, and the amounts produced depended on the nature and concentration of the aggregating agent used. The various inhibitors of thromboxane synthesis - aspirin and flurbiprofen (cyclo-oxygenase inhibitors), BW755C (a cyclo-oxygenase and lipoxygenase inhibitor) and dazoxiben (a selective thromboxane synthase inhibitor) - did not markedly inhibit aggregation. Results obtained using apyrase showed that adenosine diphosphate contributed to the aggregation process, and that its role must be acknowledged when devising means of inhibiting platelet aggregation in vivo.

Sign in / Sign up

Export Citation Format

Share Document